OncoC4 has dosed the first patient in a Phase 1 trial of ONC-783, a T-cell engager targeting cancer-specific CD24 glycoforms in advanced solid tumors. Early data shows tolerability without severe adverse events, positioning this as a potential addition to the immunotherapy landscape for cancers with limited treatment options.
Key Points
- First patient dosed; no severe adverse events or cytokine toxicity observed
- Targets cancer-specific CD24 glycoform; subcutaneous delivery reduces systemic exposure
- Phase 1 focuses on colorectal, ovarian, pancreatic, and breast cancers
Longevity Analysis
T-cell engagers represent a distinct mechanism within immuno-oncology — they bridge the patient's own immune cells directly to cancer cells without requiring prior ex vivo engineering. The subcutaneous formulation strategy addresses a critical practical concern: cytokine release toxicity has historically limited systemic dosing in cell-based therapies. For patients with solid tumors refractory to checkpoint inhibitors or conventional chemotherapy, a well-tolerated cell engager could extend treatment options and functional lifespan. The focus on CD24 glycoforms suggests precision targeting of cancer-associated epitopes rather than pan-tumor markers, which may reduce off-target immune activation. Success here would validate both the neoCD24 platform and the pharmacokinetic principle that local, gradual exposure can improve the therapeutic window.
Original published by LT Wire.